Erespal 80 mg 30 pcs. film-coated tablets

Compound

The composition of the tablets is as follows: each tablet contains the active ingredient fenspiride hydrochloride , as well as additional substances: hypromellose, calcium hydrogen phosphate, macrogol 6000, silicon dioxide, povidone, titanium dioxide, magnesium stearate, glycerol .
The composition of cough syrup is as follows: active substance fenspiride hydrochloride , additional substances: flavoring agent, glycerol, licorice extract, Sunset Yellow S, propyl parahydroxybenzoate, methyl parahydroxybenzoate, sucrose, saccharin, potassium sorbate, water.

Release form, composition and packaging

Orange syrup Formation of sediment is possible, which disappears upon shaking.

Excipients:

flavoring composition with hints of honey smell, licorice root extract, vanilla tincture, glycerol, sunset yellow dye (sunset yellow S), methyl parahydroxybenzoate, propyl parahydroxybenzoate, saccharin, sucrose, potassium sorbate, purified water.

150 ml - brown plastic bottles (1) - cardboard packs.

Pharmacodynamics and pharmacokinetics

Erespal (Eurespal) prevents bronchoconstriction and slows down exudation . The anti-inflammatory effect that fenspiride is due to inhibition of arachidonic acid metabolism. Antibronchoconstrictor effects are produced due to inhibition of the process of secretion of biologically active substances: histamine , serotonin , bradykinin . In addition, the drug blocks α-adrenergic receptors, upon stimulation of which there is an increase in the production of bronchial secretions.

Prevents bronchospasm . If the drug is prescribed in large doses, it reduces the production of various inflammatory factors.

The medicine is well absorbed from the gastrointestinal tract. The highest concentration of the active substance in the blood plasma is observed approximately 2.5 hours after oral administration. The half-life is 12 hours.

Approximately 90% of the drug is excreted through the kidneys, the remaining 10% is excreted through the intestines.

pharmachologic effect

The anti-inflammatory and anti-bronchoconstrictor activity of Erespal® is due to the fact that fenspiride reduces the production of a number of biologically active substances (cytokines, especially tumor necrosis factor α (TNF-α), arachidonic acid derivatives, free radicals), which play an important role in the development of inflammation and bronchospasm.

Inhibition of arachidonic acid metabolism by fenspiride is potentiated by blockade of histamine H1 receptors, because histamine stimulates the formation of its products (prostaglandins and leukotrienes). Fenspiride blocks α-adrenergic receptors, the stimulation of which is accompanied by an increase in the secretion of the bronchial glands. Thus, fenspiride reduces the effect of a number of factors that contribute to the hypersecretion of proinflammatory factors, the development of inflammation and bronchial obstruction.

Fenspiride also has an antispasmodic effect.

Indications for use of Erespal

What are the tablets and syrup for? Indications for the use of the drug are diseases of the upper and lower respiratory tract of humans.

What does the medicine help with:

• laryngitis , nasopharyngitis ;
• bronchitis;
• tracheobronchitis;
• bronchial asthma (as part of complex treatment);
• hoarseness, cough, tickling, disturbing patients with whooping cough , influenza , measles ;
• infectious respiratory tract diseases, the symptom of which is cough;
• sinusitis , otitis media .

Thus, according to the annotation, indications for the use of Erespal are diseases accompanied by cough and other symptoms of respiratory tract diseases. Indications for the use of syrup are the same as for the use of the drug in tablets. When prescribing a treatment complex, the doctor determines which form of the drug is preferable.

Erespal 80 mg 30 pcs. film-coated tablets

pharmachologic effect

Anti-inflammatory antibronchoconstrictor agent.

Composition and release form Erespal 80 mg 30 pcs. film-coated tablets

Film-coated tablets - 1 tablet:

• Active ingredients: fenspiride hydrochloride - 80 mg;
• Excipients: calcium hydrogen phosphate - 104.5 mg, hypromellose - 100 mg, povidone K30 - 12.8 mg, colloidal anhydrous silicon dioxide - 0.5 mg, magnesium stearate - 2.2 mg;
• Shell composition: titanium dioxide - 0.841 mg, glycerol - 0.263 mg, hypromellose - 4.37 mg, macrogol 6000 - 0.263 mg, magnesium stearate - 0.263 mg.

15 pcs. - blisters (2) - cardboard packs.

Description of the dosage form

White film-coated tablets, round, biconvex.

Directions for use and doses

Inside.

For adults, the drug is prescribed 80 mg (1 tablet) 2-3 times a day.

The maximum daily dose is 240 mg. The duration of treatment is determined by the doctor.

Pharmacodynamics

The anti-inflammatory and anti-bronchoconstrictor activity of fenspiride is due to a decrease in the production of a number of biologically active substances (cytokines (especially TNF-α), arachidonic acid derivatives, free radicals), which play an important role in the development of inflammation and bronchospasm.

The inhibition of arachidonic acid metabolism by fenspiride is potentiated by its H1-antihistamine effect, because histamine stimulates the metabolism of arachidonic acid with the formation of prostaglandins and leukotrienes. Fenspiride blocks α-adrenergic receptors, the stimulation of which is accompanied by an increase in the secretion of the bronchial glands. Thus, fenspiride reduces the effect of a number of factors that contribute to the hypersecretion of proinflammatory factors, the development of inflammation and bronchial obstruction.

Fenspiride also has an antispasmodic effect.

Pharmacokinetics

Suction

After oral administration, Cmax is achieved within 6 hours.

Withdrawal

T1/2 - 12 hours. Excreted mainly by the kidneys.

Indications for use Erespal 80 mg 30 pcs. film-coated tablets

Diseases of the upper and lower respiratory tract:

• rhinopharyngitis and laryngitis;
• tracheobronchitis;
• bronchitis (with or without chronic respiratory failure);
• bronchial asthma (as part of complex therapy);
• respiratory phenomena (cough, hoarseness, sore throat) with measles, whooping cough, influenza;
• infectious diseases of the respiratory tract accompanied by cough, when standard antibiotic therapy is indicated.

Otitis and sinusitis of various etiologies.

Contraindications

• children under 18 years of age (Erespal® syrup should be used to treat children and adolescents under 18 years of age);
• hypersensitivity to the active substance and/or any of the components of the drug.

Application Erespal 80 mg 30 pcs. film-coated tablets during pregnancy and breastfeeding

There are no or limited data on the use of Erespal® in pregnant women. The use of the drug during pregnancy is not recommended.

Fenspiride therapy is not a reason to terminate an ongoing pregnancy.

Erespal® should not be used during breastfeeding due to the lack of data on the penetration of fenspiride into breast milk.

Erespal® syrup should be used to treat children and adolescents under 18 years of age.

special instructions

Erespal® syrup should be used to treat children and adolescents under 18 years of age.

Impact on the ability to drive vehicles and operate machinery

No studies have been conducted to study the effect of Erespal® on the ability to drive vehicles and operate machinery. Patients should be aware of the possible development of drowsiness while taking Erespal®, especially at the beginning of therapy or when combined with alcohol intake, and should be careful when driving vehicles and when performing work that requires a high speed of psychomotor reactions.

Overdose

In case of an overdose of the drug (cases of overdose have been reported when taking the drug at a dose of more than 2320 mg), you should immediately seek medical help.

Symptoms: drowsiness or agitation, nausea, vomiting, sinus tachycardia.

Treatment: gastric lavage, ECG monitoring, maintaining vital body functions.

Side effects Erespal 80 mg 30 pcs. film-coated tablets

The patient should be informed of the need to inform the doctor about any, incl. undesirable reactions and sensations not mentioned below, as well as changes in laboratory parameters during therapy with Erespal®.

The most common adverse reactions to the drug Erespal® are observed in the digestive system.

The frequency of adverse reactions that may occur during therapy is given in the following gradation: very often (>1/10); often (>1/100, 1/1000, 1/10,000,

From the cardiovascular system: rarely - moderate tachycardia, the severity of which decreases with decreasing dose of the drug; unknown frequency* - a feeling of palpitations and a decrease in blood pressure, possibly associated with tachycardia.

From the digestive system: often - gastrointestinal disorders, nausea, epigastric pain; unknown frequency* - diarrhea, vomiting.

From the side of the central nervous system: rarely - drowsiness; unknown frequency* - dizziness.

From the skin and subcutaneous fat: rarely - erythema, rash, urticaria, angioedema, fixed erythema pigmentosa; unknown frequency* - itching, toxic epidermal necrolysis, Stevens-Johnson syndrome.

General disorders: unknown frequency* - asthenia, increased fatigue.

* Data from post-registration use.

Drug interactions

No special studies have been conducted on the interaction of fenspiride with other drugs.

Due to the possible sedative effect when taking histamine H1 receptor blockers, the use of Erespal® in combination with drugs that have a sedative effect or with alcohol is not recommended.

Contraindications

The following contraindications to taking the drug are noted:

• high level of sensitivity to the active substance or other components;
• children up to two years of age.

The syrup is used with caution to treat people who have fructose intolerance , glucose-galactose malabsorption , diabetes mellitus , sucrase or isomaltase deficiency, since the syrup contains sucrose.

Side effects

If Eurespal syrup or tablets cause any side effects, you should definitely consult a doctor and inform him in detail about what is happening.

When treated with Erespal, the following side effects may occur:

• In the functioning of the cardiovascular system: in rare cases, tachycardia , which decreases when the dose of the drug is reduced.
• In the functioning of the gastrointestinal tract: stomach and intestinal disorders, pain in the epigastrium, nausea are often observed; Sometimes vomiting and diarrhea .
• In the functioning of the central nervous system: drowsiness is rarely observed, dizziness is sometimes observed.
• Asthenia and severe fatigue may occur
• Skin reactions: in rare cases, urticaria , erythema , rash are observed, and sometimes skin itching may be bothersome.
• You may be sensitive to the dye contained in the product.

Instructions for use of Erespal (Method and dosage)

The drug in tablets is used only for the treatment of adult patients. During treatment, the instructions for use of tablets and syrup must be strictly followed.

Instructions for Erespal tablets

The medicine should be taken before meals. For chronic inflammatory diseases, it is recommended to take two 80 mg tablets per day - morning and evening. In the acute course of the disease, the doctor may prescribe a course of treatment that involves taking three tablets - morning, afternoon and evening. The doctor can prescribe an individual plan for how to take the pills. The duration of therapy is also determined individually.

Instructions for Erespal cough syrup

The syrup can be taken by adults; it is also prescribed for children after the age of twelve. You can take from 3 to 6 tablespoons of the product (45–90 ml) per day. The course of treatment for children and adults lasts as many days as prescribed by the attending physician.

The medicine in syrup form is not prescribed to children under 2 years of age.

Erespal for children

It is prescribed taking into account how old the child is and how much he weighs. In this case, the dosage of the syrup is carried out so that the daily dose of cough suppressant is not exceeded. The instructions for syrup for children stipulate that the daily dose is divided into 2 or 3 doses. The syrup should be drunk before meals.

The drug is not prescribed for children under 2 years of age. If treatment of respiratory diseases is required for children under one year of age, the doctor prescribes safe analogues for children of this age.

It is recommended to consume 4 mg of the drug per 1 kg of child’s body weight per day.

Children weighing less than 10 kg are prescribed 2-4 teaspoons of the product per day (10–20 ml). Children weighing more than 10 kg are prescribed 2-4 tablespoons of the product per day (20–60 ml).

How many days a child takes this remedy depends on the disease and the doctor’s recommendations. Reviews of the syrup indicate that an improvement in the condition is noted after 2-3 days of such treatment.

Dosage regimen

For adults

the drug is prescribed 80 mg (1 tablet) 2-3 times a day or 3-6 tablespoons (45-90 ml) of syrup per day. 1 tablespoon contains 30 mg of fenspiride hydrochloride and 9 g of sucrose.

The maximum daily dose is 240 mg. The duration of treatment is determined by the doctor.

Erespal® in tablet form is not intended for the treatment of children and adolescents under 18 years of age

. For use of the drug in this category of patients, Erespal® in the form of syrup is recommended.

Children and teenagers

the drug is prescribed at a rate of 4 mg/kg body weight/day.
Children aged 0 to 2 years (body weight up to 10 kg)
- 2-4 teaspoons of syrup (10-20 ml)/day, can be added to a bottle with food (1 teaspoon contains 10 mg of fenspiride hydrochloride and 3 g of sucrose ).
Children aged 2 to 16 years (body weight more than 10 kg)
- 2-4 tablespoons of syrup (30-60 ml)/day.

The drug should be taken before meals. The syrup should be shaken before use.

special instructions

Often patients have a question about whether Erespal is an antibiotic or not. In fact, treatment with Erespal cannot replace antibiotic therapy. Therefore, if necessary, an additional antibiotic is prescribed.

People with diabetes are prescribed the drug in tablets, since the syrup contains sucrose.

sunset yellow in the syrup, people with intolerance to acetylsalicylic acid , as well as other NSAIDs, may develop bronchospasm.

No studies have been conducted that would allow conclusions to be drawn about the effect of Erespal on the ability to drive vehicles and work with precision mechanisms. However, drowsiness may occur when using it, especially if the drug is combined with sedatives or alcohol. It should be noted that such a combination may lead to a reaction disorder.

Erespal's analogs

Level 4 ATX code matches:
Siresp

Daxas

Inspiron

In pharmacy chains you can find similar drugs that have the same properties. Analogs of Erespal syrup and tablets in terms of effects on the human body are Stoptussin , Fenspiride , Ascoril , Fluditek , Lazolvan , Ambrobene . The price of analogues can be either higher or lower. But, despite the desire to find cheaper analogues, you should ask your doctor about what you can replace 80 mg tablets or Erespal syrup with. In some cases, Erespal can be replaced with the drug Bronchicum . It is used for bronchitis, both dry and wet cough.

Which is better: Erespal or Sinekod?

Sinekod is a drug that is a direct-acting antitussive drug. Its active ingredient is butamirate . This remedy is used primarily for non-productive coughs. It is not recommended to take Erespal and Sinekod at the same time. In this case, you should definitely consult a doctor.

Which is better: Erespal or Lazolvan?

Only a doctor should prescribe a drug for the treatment of an adult or child. Erespal more effectively reduces inflammatory processes, and Lazolvan promotes the liquefaction and removal of sputum. That is, Lazolvan is used for wet coughs. Often patients are also interested in whether it is possible to take Erespal and Lazolvan at the same time. The compatibility of these drugs is acceptable. However, only a doctor can prescribe Lazolvan and Erespal together, since compliance with a special regimen for taking these drugs is required.

Which is better: Erespal or Ambrobene?

Patients also wonder whether Erespal and Ambrobene can be used together during treatment. The active ingredient of the drug Ambrobene, like Lazolvan, is ambroxol hydrochloride . Therefore, the answer to the question of what to prefer, Erespal or Ambrobene, is similar.

Which is better: Prospan or Erespal?

Prospan is a drug with a mucolytic effect, the basis of which is a dry extract of ivy leaves. However, only a doctor can determine which drug should be used for a cough, runny nose, etc.

Which is better: Erespal or Askoril?

The drug Ascoril contains three active substances - salbutamol , bromhexine and guaifenesin . It acts on the body as a bronchodilator and mucolytic. Erespal and Ascoril are prescribed at the same time, only by a doctor according to indications. The patient also cannot independently answer which is better - Erespal or Ascoril, since the diagnosis and individual characteristics of the patient must be taken into account.

People very often have questions about combining Erespal with other cough medicines. For example, can Erespal and Fluditec together? Is cough treatment carried out in such a way that Erespal and ACC can be used together in one treatment regimen? Despite the fact that there are no strict instructions on the incompatibility of these drugs, you cannot combine any cough suppressants on your own, without consulting a doctor.

Thus, before answering which cough to take this or that drug, you need to carefully study the instructions and consult with your doctor. For which cough a particular syrup or tablet is prescribed and drunk depends on its active substance and effect on the body.

Use of the drug erespal in the treatment of inflammatory diseases of the upper respiratory tract

In January 1998, the pharmaceutical company Servier introduced in Russia a new drug, fespiride (erespal), intended for the treatment of inflammatory diseases of the mucous membranes of the respiratory tract.

The action of fenspiride is aimed at various parts of the inflammatory process: the formation of arachidonic acid derivatives, the synthesis and release of histamine and cytokines. This fact sharply distinguishes it from the general range of anti-inflammatory, steroidal and non-steroidal drugs, which have an effect primarily at the level of arachidonic acid metabolism. Fenspiride is an adrenergic receptor antagonist and has a chemotoxic effect.

The effect of fenspiride on the metabolism of arachidonic acid is mediated through calcium metabolism, which is a regulator of the action of phospholipase A. By inhibiting the flow of calcium into macrophages, fespiride reduces the activity of phospholipase A2 (phospholipase A2 promotes the formation of arachidonic acid), resulting in a decrease in the synthesis of prostaglandins and leukotrienes. This is the main difference between fenspiride and non-steroidal anti-inflammatory drugs, which, by blocking the cyclooxygenase pathway, reduce the synthesis of prostaglandins, which increases the synthesis of leukotrienes, biologically active compounds that have an irritating effect on the mucous membranes of the bronchi and gastrointestinal tract. The mechanism of action of fenspiride also differs from corticosteroids, which affect phospholipase A2 through an inhibitory protein.

Thus, being neither a steroidal nor a non-steroidal anti-inflammatory drug, fenspiride has an original effect on inflammatory processes in the mucous membrane of the respiratory tract, as it affects all inflammatory mediators, and not just the metabolism of arachidonic acid.

The clinical effectiveness of Erespal was confirmed in patients with chronic bronchopulmonary diseases with broncho-obstructive syndrome, both according to the positive dynamics of clinical symptoms (cough or sputum), and according to gasometry (PaO2) and pulmonary ventilation indicators (FEV1).

The drug demonstrated good tolerability by patients even with long-term use.

In addition, the rules for taking Esperal are simple and easy: 2-3 tablets per day, with an unlimited duration of use.

Considering the pathogenetic commonality of diseases of the upper and lower respiratory tract, we decided to conduct a clinical trial of erespal for inflammatory diseases of the mucous membrane of the nasal cavity, paranasal sinuses, and larynx.

• The use of erespal in patients with chronic sinusitis

10 patients with chronic sinusitis received treatment with erespal. Of these, 6 suffered from chronic purulent sinusitis in the acute stage, 4 from chronic polyposis sinusitis in combination with bronchial asthma.

The course of treatment was 14 days. The drug was prescribed one tablet three times a day with meals. Taking erespal was combined with conventional treatment. The control group consisted of patients with the same forms of chronic sinusitis, but who received only traditional therapy. In case of exacerbation of chronic purulent sinusitis, general antibacterial and local anti-inflammatory treatment was carried out (puncture of the paranasal sinuses and Proetz movement). Patients with chronic polypous sinusitis in combination with bronchial asthma underwent nasal polypotomy. The results were assessed based on clinical data. To objectify the positive dynamics, mucociliary transport of the nasal mucosa was studied using a saccharin test.

The study showed that in a group of patients with exacerbation of chronic purulent sinusitis who received complex treatment, including erespal, the inflammatory process in the paranasal sinuses was relieved much faster than in the control group. The maximum duration of treatment was 10 days; the number of punctures in each case did not exceed three. We obtained a significant decrease in the time of mucociliary transport in the nasal cavity as a result of taking Erespal in this group of patients (25 minutes before treatment and 16 minutes after). In the control group, the maximum duration of treatment was one month. The maximum number of punctures in individual cases reached seven.

In the group of patients with chronic polyposis sinusitis in combination with bronchial asthma, erespal was used before nasal polypotomy as a preoperative preparation in combination with desensitizing agents. In the control group, during the preoperative period, patients received only desensitizing agents—claritin, hismanal.

It was noted that in patients who were prescribed erespal in combination with desensitizing drugs for 7 days, reactive phenomena from the mucous membrane of the nasal cavity (swelling, mucous discharge) were almost completely stopped. This made it possible to carry out surgical treatment (removal of polyps) in the most adequate conditions. In the postoperative period, reactive phenomena from the nasal cavity were minimal. Nasal breathing was restored on the third day.

In the control group of patients with chronic polyposis sinusitis, preoperative preparation took 14 days or more. In the postoperative period, reactive phenomena were more pronounced. Nasal breathing was restored more slowly, up to 10 days.

Thus, the complex use of erespal in the complex treatment of patients with chronic purulent and polypous sinusitis has shown its effectiveness in the treatment of inflammatory diseases of the upper respiratory tract.

• Experience of using erespal in complex therapy of inflammatory diseases of the larynx and trachea

Therapy of the inflammatory process in the larynx and trachea is associated with an effect on the secretory activity of the mucous glands and inflammatory mediators. The larynx is under the influence of the autonomic nervous system [5], in addition, cellular receptors of biologically active substances, in particular neuropeptides - histamine, etc., are abundantly represented in this organ [1], which is of significant importance in the pathogenesis of acute inflammatory edema of the larynx [2] and subglottic space and clinically often manifests as dysphonia [4].

We used Erespal in the complex treatment of subacute and exacerbations of chronic laryngotracheitis. The group of observed patients consisted of 10 men and 2 women aged from 23 to 62 years, who applied for the first time (8 people) or repeatedly (4 people) to the phoniatric office of the St. Petersburg Research Institute of Ear, Throat, Nose and Speech. Of these, 7 patients were smokers.

Patients complained of sore throat, persistent dysphonia, moderate cough for 2-4 weeks - as a consequence of a cold. Laryngoscopy revealed hyperemia, moderate swelling of the vocal folds and subglottic space, and the presence of thick mucus in the larynx.

Patients received the following therapy: fractional infusion of streptomycin into the larynx and ascorbic acid 0.3 g three times a day. Antihistamines [3], expectorants and calcium gluconate were replaced with erespal (1 tablet three times a day).

Most patients (11 people) were cured within 5-8 days. One patient was treated for 15 days due to elevated blood sugar levels, which required additional therapy.

During treatment, no adverse reactions or intolerance to the drug were observed.

Smoking patients suffering from chronic bronchitis were recommended to take the drug at a dose of 1 tablet twice a day.

We consider the use of erespal quite effective in the complex treatment of subacute laryngotracheitis and exacerbations of chronic laryngitis and recommend its widespread use in the treatment of these types of pathologies. Thus, erespal can be recommended for use in inflammatory diseases of both the lower and upper respiratory tract.

Literature
1. Aslanyan G. G. Cellular receptors for histamine and bradykinin in the larynx and trachea (Message 1). Vestn. otorhinolar, 1995, No. 1, p. 35–39. 2. Mitin Yu. V. Acute laryngotracheitis in children. M.: Medicine, 1986, p. 208. 3. Frantsuzov B. L., Frantsuzova S. B. Drug therapy for diseases of the ear, nose and throat. Kyiv: Health, 1988, p. 280. 4. Charakhalashvili G. E. On the importance of reflexogenic zones of the larynx in the treatment of professional singers. Vestn. otorhinol. 1989, No. 1, p. 59. 5. Shvalev N.V. The role of autonomic innervation in the healing of damaged tissues of the larynx and the formation of its cicatricial stenosis: Abstract of thesis. Ph.D. honey. Sci. St. Petersburg, 1997, p. 22. 6. Olivieri D. Del Donno M/ Etude de l'action du fenspiride (pneumorel 80 mg) sur la clairance mucociliaire chez le bronchitique chronique. JIM 1987; 96, 365–8.

Spectrum of action of fenspiride

Prevents the direct anti-inflammatory effect of histamine and the effect of histamine on the synthesis of anti-inflammatory metabolites of arachidonic acid. It has a statistically significant antagonistic effect on histamine H1 receptors.

It affects the adrenergic nervous system, being an antagonist of 1-adrenergic receptors.

It has a pronounced inhibition of the secretion of tumor necrosis factor (the effect depends on the dose).

Leads to a decrease in chemotaxis factors and thus reduces the migration of inflammatory cells and reduces their total number (the effect depends on the dose).

Reduces pathological bronchial hypersecretion, reducing the formation of inflammatory mediators such as histamine, prostaglandins, leukotrienes, cytokines.

Increases the speed of mucociliary transport in patients with chronic bronchitis by approximately 30%. (When using 3 tablets per day for one month).

Prevents bronchoconstriction.

Reviews about Erespal

Reviews of Erespal tablets and syrup are both positive and negative. Positive reviews are mainly left by those who took the product or gave it to children after a doctor’s prescription. In particular, the rapid action of the drug, a decrease in the manifestations of the disease - cough, shortness of breath, and an improvement in the general well-being of the patient are noted. Reviews from doctors about Erespal syrup are also mostly positive.

However, there are also negative opinions about the drug on various resources. Patients note the manifestation of some side effects - weakness, insomnia, tachycardia, nausea, etc. Often negative opinions are left by those who started treatment with the drug on their own, without determining what kind of cough this medicine is used for, whether it can be taken for a dry cough, how to take it - before or after eating. It should be borne in mind that Erespal is a potent medicine, so it should not be used based only on the statement of forum members that the drug was recommended by Dr. Komarovsky or another expert.

Erespal price, where to buy

Important! On February 14, 2021, the healthcare surveillance service Roszdravnadzor announced the withdrawal from circulation of the drug Erespal in the form of syrup and tablets. This decision was made by the manufacturer of the drug itself, due to the suspension by the French agency ANSM of the registration certificates of drugs containing fenspiride .

Before the ban, the price of Erespal cough syrup 150 ml averaged 250-300 rubles. The price of Erespal in tablets was approximately 400-500 rubles. for 30 tablets of 80 mg. The cost of tablets in Ukraine is approximately 120-140 UAH. for 30 tablets.

How much Erespal tablets or syrup cost in cities such as Odessa, Kharkov can be found out exactly at specific points of sale.

• Online pharmacies in UkraineUkraine
• Online pharmacies in KazakhstanKazakhstan

Pharmacy24

• Erespal 200 mg/100 ml 150 ml syrup Laboratories Serv'e Industry, France
  82 UAH.order
• Erespal 80 mg No. 30 tablets Laboratories Serv'e Industry, France

  118 UAH order

PaniPharmacy

• Erespal liquid Erespal syrup 200mg/100ml 150ml France, Servier Industrie

  97 UAH order

• Erespal tablets Erespal tablets. 80 mg No. 30 France, Servier Industrie

  136 UAH order

show more